Insider trading

Period: 120 months Stock: VRTX Plan: Not stated × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

548 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

548 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

548 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

548 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
548 decisions over 120 months Remove this filter
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
548 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

548 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
13 Mar 2023
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated 6×
$783.35K 2,666 at 293.83
4.8%
10 Mar 2023
WAGNER CHARLES F JR EVP & Chief Financial Officer
Sold, plan not stated 8×
$604.71K 2,088 at 289.61
3.6%
27 Feb 2023
Sold, plan not stated 3×
$1.45M 5,034 at 287.47
8.2%
27 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 3×
$1.22M 4,238 at 287.51
11.7%
27 Feb 2023
Ambrose Kristen SVP & Chief Accounting Officer
Sold, plan not stated 3×
$347.07K 1,207 at 287.55
14.2%
27 Feb 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 3×
$101.77K 354 at 287.48
0.6%
22 Feb 2023
Sold, plan not stated 5×
$706.68K 2,401 at 294.33
3.5%
21 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$1.18M 4,002 at 293.77
9.0%
21 Feb 2023
Sold, plan not stated 4×
$705.60K 2,402 at 293.75
3.4%
21 Feb 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 4×
$141.00K 480 at 293.75
0.8%
14 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 6×
$1.91M 6,398 at 298.70
11.8%
14 Feb 2023
Sold, plan not stated 6×
$1.91M 6,398 at 298.68
7.8%
14 Feb 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 2×
$655.16K 2,181 at 300.39
3.5%
14 Feb 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 5×
$95.53K 320 at 298.52
0.5%
13 Feb 2023
Sold, plan not stated 4×
$1.46M 4,887 at 298.92
5.6%
13 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$1.43M 4,798 at 298.90
8.1%
13 Feb 2023
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 5×
$82.22K 275 at 298.99
0.4%
13 Feb 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated
$33.94K 113 at 300.39
0.2%
6 Feb 2023
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 6×
$399.02K 1,304 at 306.00
1.9%
31 Jan 2023
SACHS BRUCE I Director
Sold, plan not stated
$390.01K 1,200 at 325.01
2.8%
31 Jan 2023
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated
$34.45K 106 at 325.00
0.3%
30 Jan 2023
CARNEY LLOYD Director
Sold, plan not stated 3×
$865.41K 2,700 at 320.52
39.4%
27 Jan 2023
Lee Yuchun Director
Sold, plan not stated 3×
$460.18K 1,429 at 322.03
43.3%
26 Jan 2023
Lee Yuchun Director
Sold, plan not stated 6×
$1.27M 4,000 at 318.33
68.1%
Sold half or more
25 Jan 2023
Kewalramani Reshma CEO & President
Sold, plan not stated
$3.15M 10,000 at 315.05
10.0%
25 Jan 2023
Lee Yuchun Director
Sold, plan not stated 3×
$1.26M 4,000 at 313.96
68.1%
Sold half or more
24 Jan 2023
Lee Yuchun Director
Sold, plan not stated 2×
$1.25M 4,000 at 312.69
68.1%
Sold half or more
23 Jan 2023
Lee Yuchun Director
Sold, plan not stated
$664.29K 2,129 at 312.02
53.2%
Sold half or more
18 Jan 2023
Lee Yuchun Director
Sold, plan not stated
$137.98K 442 at 312.17
19.1%
17 Jan 2023
Lee Yuchun Director
Sold, plan not stated
$1.25M 4,000 at 312.03
68.1%
Sold half or more
15 Nov 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated
$10.49K 34 at 308.61
0.1%
7 Nov 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 7×
$394.86K 1,303 at 303.04
3.5%
2 Nov 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 7×
$100.05K 320 at 312.64
0.8%
24 Oct 2022
Sold, plan not stated
$192.51K 621 at 310.00
13.3%
18 Oct 2022
Sanna Bastiano EVP, Cell & Genetic Therapies
Sold, plan not stated 2×
$537.86K 1,791 at 300.31
4.4%
15 Aug 2022
Sold, plan not stated 6×
$6.74M 22,173 at 303.93
32.9%
15 Aug 2022
Kewalramani Reshma CEO & President
Sold, plan not stated
$3.57M 11,689 at 305.06
10.5%
15 Aug 2022
Liu Joy SVP, General Counsel
Sold, plan not stated 6×
$1.14M 3,747 at 303.90
28.1%
10 Aug 2022
Sold, plan not stated 2×
$54.07K 180 at 300.40
0.3%
10 Aug 2022
Liu Joy SVP, General Counsel
Sold, plan not stated
$10.81K 36 at 300.32
0.3%
9 Aug 2022
Sold, plan not stated 2×
$1.71M 5,690 at 300.67
8.5%
9 Aug 2022
Tatsis Ourania EVP, Chief Reg. & Quality Off.
Sold, plan not stated 5×
$418.56K 1,400 at 298.97
2.9%
9 Aug 2022
Liu Joy SVP, General Counsel
Sold, plan not stated
$283.80K 946 at 300.00
6.6%
8 Aug 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 5×
$381.47K 1,304 at 292.54
3.5%
8 Aug 2022
Sold, plan not stated 5×
$181.97K 621 at 293.03
11.8%
29 Jul 2022
Sold, plan not stated 6×
$173.12K 621 at 278.77
10.5%
25 Jul 2022
LEIDEN JEFFREY M Executive Chairman
Sold, plan not stated 5×
$37.16M 132,079 at 281.38
98.2%
Sold half or more
19 Jul 2022
ALTSHULER DAVID EVP, Global Research and CSO
Sold, plan not stated 4×
$5.16M 17,865 at 288.65
33.1%
24 Jun 2022
Kewalramani Reshma CEO & President
Sold, plan not stated
$3.41M 11,689 at 291.30
9.5%
16 May 2022
Liu Joy SVP, General Counsel
Sold, plan not stated 5×
$33.63K 133 at 252.88
0.9%
Showing 1–50 of 548. Page 1 of 11 Older →